ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
Ò©Îï´úлÓëÒ©´ú¶¯Á¦Ñ§£¨DMPK£©Ö÷ÒªÑо¿Ò©ÎïµÄÎüÊÕ¡¢ÂþÑÜ¡¢´úлºÍÉøÍ¸µÄ¶¯Ì¬Àú³ÌÓë¼ÍÂÉ£¬ÆÀ¹ÀÒ©ÎïµÄ DMPKÌØÕ÷¶ÔÒ©ÎïµÄǰÆÚ¿ª·¢ºÍºóÆÚÁÙ´²¾«×¼ÓÃÒ©ÖÁ¹ØÖ÷Òª¡£DMPKÊÇÇŽÓÒ©Àíѧ¡¢¶¾Àíѧ¡¢Ò©¼Áѧ¡¢Ò©Îﻯѧ¡¢ÒÔÖÂת»¯Ò½Ñ§ºÍ¾«×¼Ò½Ñ§µÄÖ÷ÒªÇÅÁº¡£
µÚ26½ì¹ú¼ÊÒ©Îï¼°»¯Ñ§ÒìÎï´úлѧ»á±±ÃÀ¾Û»á(ISSX)½«ÓÚ2024Äê9ÔÂ15ÈÕÖÁ18ÈÕÔÚÃÀ¹úÏÄÍþÒÄÕÙ¿ª£¬¾Û»áÄÚÈݺ¸ÇÒ©Îï´úл¡¢Ò©´ú¶¯Á¦Ñ§¡¢ÁÙ´²Ò©Àíѧ¡¢ÉúÎïÆÊÎöºÍÒ©Îï¶¾ÀíѧµÈÁìÓò¡£¹ú¼ÊÒ©Îï¼°»¯Ñ§ÒìÎï´úлѧ»á(International Society for the Study of Xenobiotics£¬ISSX)ÊÇÒ©Îï´úлÑо¿µÄ×î¸ßѧÊõ×éÖ¯Ö®Ò»£¬Ö÷ÒªÖÂÁ¦ÓÚÈ«Çò¹æÄ£ÄÚ´ÓÊÂÒ©ÎïÓ뻯ѧÒìÎï´úл·½ÃæµÄѧÊõ½»Á÷ºÍ¹ú¼ÊÏàÖú¡£×ðÁú¿Ê±ÊÜÑû¼ÓÈë±¾´ÎÄê»á£¬×ðÁú¿Ê±Ê×´´ÈË&CEO³Â´º÷벩ʿÓë×ðÁú¿Ê±DMPKר¼ÒÃÇÆÚ´ýÓëÄúÏà¾ÛÔÚ104ºÅչλ¡£
ʱ¼ä | 9.15-9.18
ËùÔÚ | Hilton Hawaiian Village Waikiki Beach Resort, Honolulu
×ðÁú¿Ê±Õ¹Î» | 104£¬²»¼û²»É¢£¡
ΪÁËչʾ×ðÁú¿Ê±Á¢ÒìʵÁ¦ºÍÊÖÒÕЧÀÍÆ½Ì¨×îÐÂÏ£Íû£¬×ðÁú¿Ê±Ò©´ú¶¯Á¦Ñ§/¶¾´ú¶¯Á¦Ñ§ (DMPK/TK) ÈÏÕæÈ˽¯Æ·²©Ê¿½«ÒÔº£±¨ (Poster) ÐÎʽ·ÖÏíÒÔÏÂÖ÷ÌâµÄ¾«²ÊÄÚÈÝ£º
Title: Enhancing Drug - Drug Interaction Prediction by Integrating Physiologically- Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4
Session Time: Wednesday, September 18, 2024 12:30?2:30 PM
Location: Poster Session 3
Poster Number: P270
Presenting Author: Dr. Pin Jiang, Senior Director of DMPK at Medicilon
Dr. Pin Jiang Senior Director of DMPK
Dr. Pin Jiang holds a Ph.D. from China Pharmaceutical University in collaboration with School of Pharmacy, Fudan University. Dr. Jiang is postdoctoral fellow in DMPK and Pharmacometrics at Fudan University, specializes in the development of DMPK/TK for innovative drugs. He has also published papers in international journals such as DMD, EODMT, JSS and JPBA.
Having worked in the pharmaceutical R&D field for nearly 10years. Before joining Medicilon, Dr. Jiang held positions in the DMPK/TK and clinical pharmacology departments of well-known Biotech/Pharma/CRO companies (AstraZeneca Dizal Pharma, Covance, ChemPartner), focusing on small and large molecules. Dr. Jiang has been responsible for or involved in supporting hundreds of DMPK projects, including drugs, which have been approved by the Chinese NMPA and the US FDA for clinical research or market entry.
Dr. Jiang also holds significant professional affiliations, serving as a youth committee member of the Drug Metabolism Committee of the Chinese Pharmacological Society (CSSX), a committee member of the Drug Metabolism Committee of the Shanghai Pharmacological Society, a youth committee member of the Pharmacology Committee of the Shanghai Pharmaceutical Association, and a member of the International Society for the Study of Xenobiotics (ISSX).
Dr. Peggy Teng, Executive Director BD Operations
Dr. Karsten Holm, Director of Business Development
Dr. Mingzhu Zhang, VP of Business Development
×ðÁú¿Ê±µÄÁÙ´²Ç°Ò©´ú¶¯Á¦Ñ§Ð§ÀͲ¿·ÖÓµÓÐÒ»ÅúÀíÂÛ֪ʶÔúʵ¡¢ÊµÑéÂÄÀú¸»ºñµÄ¸ß¼¶×¨ÒµÈ˲ţ¬Í³Áì×ÅʵÑéÉè¼Æ¡¢ÊµÑéʵÑé¡¢ÉúÎïÆÊÎöºÍÊý¾ÝÆÊÎöµÈµÄÊÂÇé¡£
×ðÁú¿Ê±Ò©´ú¶¯Á¦Ñ§ÊµÑéÊÒÒѾͨ¹ýNMPAµÄGLPÈÏÖ¤£¬ÊµÑéÑо¿×ñÕÕICH¡¢NMPAºÍFDAµÄÖ¸µ¼ÔÔò£¬¿ÉÒÔÆ¾Ö¤¿Í»§ÐèÇóÉè¼Æ²¢¿ªÕ¹ÌåÄÚ¡¢ÌåÍâÒ©´ú¶¯Á¦Ñ§ÊÔÑ飬Ϊ¿Í»§ÌṩһÕûÌ×Ò©´ú¶¯Á¦Ñ§ÆÀ¼ÛºÍÓÅ»¯Ð§ÀÍ¡£×ðÁú¿Ê±Ò©´ú¶¯Á¦Ñ§Ð§À͸ßÖÊÁ¿µÄÊý¾Ý¡¢¸ßЧÂʵÄʵÑéÖÜÆÚ£¬Öª×ã¿Í»§´ÓÔçÆÚÒ©Îï·¢Ã÷µ½ÐÂÒ©É걨µÄÐèÇó£¬Êܵ½º£ÄÚÍâÖÚ¶à¿Í»§µÄºÃÆÀ¡£
¾Û»áʱ¼ä£º2023Äê2ÔÂ17ÈÕ 09:00-17:00
¾Û»áËùÔÚ£ºÉϺ£×¿ÃÀÑÇϲÂêÀÑÅÂÃ¹Ý (ÉϺ£ÊÐÆÖ¶«ÐÂÇøÃ·»¨Â·1108ºÅ)